Alkermes plc (ALKS) Announces Data on ALKS 5461 and ALKS 3831 to be Presented at 53rd Annual NCDEU Meeting
5/22/2013 6:56:04 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Alkermes plc (NASDAQ: ALKS) today announced that clinical data on ALKS 5461, a novel drug candidate for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, and ALKS 3831, a novel antipsychotic candidate for the treatment of schizophrenia, are scheduled to be presented at the 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Hollywood, Fla., May 28-31, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by